logo-loader

Full interview: AIM ImmunoTech CEO offers corporate update on lead drug, fundraising efforts

Published: 11:02 10 Dec 2019 EST

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels offered Proactive an update on the the biotech firm's activities over the past few months. 

Formerly known as Hemispherx Biopharma, Equels says over the past few months the company has changed its name and raised approximately $10 million from the public markets to support its lead drug cancer treatment candidate Ampligen. 

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

16 minutes ago